Skip to content
Research articles with safety and study context in view.
Your Peptide Tracker

Logging fresh findings for semaglutide, KPV, MOTS-c.

Menu

Peptide tracker questions and research answers

The name of this site can suggest a treatment tool. These answers explain what the pages provide and how to interpret the studies they discuss. The site contains no personal treatment record, reminders, mixing calculator, or prescription service. Its subject is published evidence about four peptides.

Is this a smart peptide tracker app?

No. Your Peptide Tracker is a reading resource covering semaglutide, retatrutide, MOTS-c, and KPV. It offers no downloadable app, dose log, or account for recording treatment. Tracking here means following research findings and safety information.

A personal record and a research article serve different purposes. An article can describe what happened in a trial, but it cannot assess a person's symptoms, check the identity of their medicine, or decide whether a treatment change is appropriate. Those decisions require clinical context beyond these pages.

Does the site recommend peptide doses?

The articles provide no personal dose, cycling, preparation, or mixing instructions. A trial protocol describes what researchers tested in an eligible group with specified monitoring. It is not a ready-made plan for someone outside that study.

Some peptides discussed here lack an FDA-approved prescribing label and established human treatment evidence. Converting an animal experiment into a human schedule would leave essential questions unanswered. The pages instead explain the study design, outcomes, and safety limitations, with links to the original records.

Is retatrutide approved?

As of November 3, 2026, retatrutide had no FDA-approved indication. FDA's discussion of unapproved GLP-1 drugs distinguishes it from approved products. Published trials are evidence for review, rather than approval in themselves.

The retatrutide article includes newer phase 3 publications alongside the earlier obesity study. It keeps the study population and analysis attached to the weight figures. A large reported average cannot establish that a particular preparation outside a trial matches the study medicine.

What does semaglutide evidence establish?

It supports specific findings in specific groups. STEP 1 studied weight change in adults without diabetes, while SELECT examined cardiovascular events in people with existing cardiovascular disease and excess weight. These are distinct questions.

Semaglutide is the ingredient in Ozempic, Wegovy, and Rybelsus, FDA-approved brands with different uses and formulations. A study does not determine an individual's eligibility, and a compounded preparation does not inherit an approved medicine's regulatory status. The semaglutide page discusses benefits and safety together.

Do KPV gut studies show treatment of bowel disease?

The findings covered here are from cells and mice, not clinical treatment of people with bowel disease. The PepT1 research connects cellular uptake with reduced inflammatory signaling in experimental systems. It supplies a biological question worth investigating.

It does not establish symptom relief, remission, or a safe regimen in a person. Delivery research introduces another distinction: a targeted preparation includes its carrier, not only KPV. Missing human safety information remains a limitation even when an animal result is promising.

Does a higher MOTS-c blood level mean better health?

There is no universal interpretation. The dialysis study associated higher natural MOTS-c with greater risk in a seriously ill population. That was observational research, without administering the peptide.

Other work examines exercise and muscle biology in different settings. A number's meaning depends on where it came from and why it was measured. These papers provide no personal target blood level and do not show that giving MOTS-c would reproduce the effect of exercise in humans.

Does a compounding-policy change prove effectiveness?

Policy and clinical evidence answer different questions. In its draft policy published October 30, 2026, HHS said it does not intend to take enforcement action against state-licensed pharmacies and licensed physicians compounding KPV or MOTS-c for an individual patient's prescription when its conditions are met. This is a nonbinding draft, not FDA approval; neither peptide is on FDA's 503A bulks list. Its single-active-ingredient limit excludes blends, and 503B outsourcing facilities are outside its scope.

A regulatory document cannot turn a cell finding into a human outcome. Equally, a promising trial does not settle every product-quality or access question. Each type of source needs to be read for the claim it can support, with its date, scope, and remaining uncertainties intact.

How can an error be reported?

The contact page describes the corrections mailbox. A useful note identifies the page, the disputed wording, and a publication or policy document that supports a change. Personal medical records are unnecessary for an article correction.

The references page makes it easier to locate the cited source. If an article seems stronger than its evidence, naming the missing qualification is helpful: the species, study population, preparation, follow-up period, or kind of outcome may be the detail that changes the claim.

Explore the sources